SCHEMBL5035193

SCHEMBL5035193

O=C(O)c1cnc(N(C(=O)c2ccc(Cl)cc2Cl)c2ccc(Cl)cc2)s1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.47
PPARG P37231 1/20 0.47
NCOA2 Q15596 1/20 0.47
NCOA1 Q15788 1/20 0.47
NCOA3 Q9Y6Q9 1/20 0.47
CYP3A4 P08684 6/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
TSHR P16473 1/20 0.43
CASP1 P29466 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
L3MBTL1 Q9Y468 2/20 0.42
ALDH1A1 P00352 2/20 0.42
KDM4E B2RXH2 1/20 0.42
SRD5A2 P31213 1/20 0.37
MRGPRX4 Q96LA9 1/20 0.37
FFAR2 O15552 1/20 0.36
MEN1 O00255 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5035896 0.87 CYP3A4 (0.39) HPGDPPARGNCOA2NCOA1NCOA3
SCHEMBL5035234 0.86 ALDH1A1 (0.41) HPGDPPARGNCOA2NCOA1NCOA3
SCHEMBL5032621 0.85 CYP3A4 (0.53) HPGDPPARGNCOA2NCOA1NCOA3
SCHEMBL5032583 0.85 CYP3A4 (0.44) HPGDPPARGNCOA2NCOA1NCOA3
SCHEMBL5032505 0.84 CYP3A4 (0.48) HPGDPPARGNCOA2NCOA1NCOA3
SCHEMBL5032542 0.84 HPGD (0.42) HPGDPPARGNCOA2NCOA1NCOA3
SCHEMBL5032526 0.82 CYP3A4 (0.49) HPGDPPARGNCOA2NCOA1NCOA3
SCHEMBL5034874 0.82 HPGD (0.42) HPGDPPARGNCOA2NCOA1NCOA3
SCHEMBL5035252 0.81 CYP3A4 (0.43) HPGDPPARGNCOA2NCOA1NCOA3
SCHEMBL5032575 0.81 CYP3A4 (0.43) HPGDPPARGNCOA2NCOA1NCOA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7371751-B2 Thiazole derivatives HOFFMANN-LA ROCHE INC. (US) 2008-05-13 US disclosed
EP-1694673-B1 THIAZOLE DERIVATES HOFFMANN LA ROCHE (CH) 2008-01-16 EP disclosed
EP-1694673-A1 NOVEL THIAZOLE DERIVATES F.HOFFMANN-LA ROCHE AG (CH) 2006-08-30 EP disclosed
US-20050153962-A1 Thiazole derivatives HOFFMANN-LA ROCHE INC. 2005-07-14 US disclosed
WO-2005058887-A1 NOVEL THIAZOLE DERIVATES F. HOFFMANN-LA ROCHE AG (CH) 2005-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050153962-A1 Thiazole derivatives CNR1, CNR2, GPR119 HPGD 1922/4885PPARG 33/4885NCOA2 375/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.